German-based company Genekam Biotechnology has developed the first potential therapeutic molecule candidate against Zika viruses.

The Zika virus infects pregnant women, leading to disorders and newborns with microencephaly (child with a smaller head), as well as lifelong handicap.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Genekam said that the choice to detect and prevent the Zika viruses until now is diagnostic.

Based on experiments, it is proved that Genekam Zika-molecule inhibits the Zika virus infection and is likely to be non-toxic.

The company plans to carry out more studies until the molecules are used on trial for human beings.

See Also:

    According to Genekam, the molecule can accelerate the clinical trial process and remains non-toxic in further studies.

    How well do you really know your competitors?

    Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

    Company Profile – free sample

    Thank you!

    Your download email will arrive shortly

    Not ready to buy yet? Download a free sample

    We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

    By GlobalData
    Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
    "Based on experiments, it is proved that Genekam Zika-molecule inhibits the Zika virus infection and is likely to be non-toxic."

    Genekam is specialised in the development of solutions for viruses, particularly influenza, Ebola, MERS and mosquito borne flaviviruses.

    The Zika virus is a member of the virus family Flaviviridae and the genus Flavivirus, and is spread by daytime-active Aedes mosquitoes, such as A aegypti and A albopictus and is related to the dengue, yellow fever, Japanese encephalitis, and West Nile viruses.

    The infection often causes no or only mild symptoms, similar to a very mild form of dengue fever.

    Zika can also spread from a pregnant woman to her fetus, which may result in microcephaly, severe brain malformations, and other birth defects.

    Image: Genekam therapeutic molecule candidate Photo: courtesy of PRNewsFoto/Genekam Biotechnology AG.